Fate Therapeutics (FATE) Stock: Buy, Sell, or Hold?
FATE - Fate Therapeutics, Inc.
$2.34
0.04 (1.52%)
â˛
5d:
-0.64%
30d:
-4.69%
90d:
-21.91%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When FATE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: FATE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: FATE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: FATE is currently trading at $2.33, which is considered fair relative to its 30-day fair value range of $2.36 to $2.52.
Technical Outlook: Technically, FATE is in a downtrend. The price is currently testing key support at $2.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FATE scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.74 (+149.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FATE is in a downtrend. The price is currently testing key support at $2.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FATE scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.74 (+149.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.36 -
$2.52
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 149.8% below Wall St target ($5.74)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.36 -
$2.52
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.27
Resistance Level
$2.63
Current Trend
Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.38
Wall Street Target
$5.74
(+149.8%)
Revenue Growth (YoY)
9.2%
Share & Embed Analysis
Last updated: October 02, 2026 10:00 AM ET
Data refreshes hourly during market hours. Next update: 11:00 AM
Data refreshes hourly during market hours. Next update: 11:00 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FATE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 55 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$570 | 50 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 58 HOLD |
|
IMCR
Immunocore Holdings Ltd |
STRONG BUY
17 analysts |
$63 | 74 BUY |
